Farms.com Home   News

Congress Passes Tax Extenders bill

On Dec. 16 the U.S. Senate approved legislation to extend a number of expiring tax provisions and President Barack Obama signed it into law on Dec. 19.

The bill, H.R. 5771, called the Tax Increase Prevention Action of 2014, passed the Senate by a 76-14 vote. It passed the House on Dec. 3 by a 378-46 vote.

The bill included the extension through tax year 2014 for dozens of individual and small business expenses. The key ones for farmers are Section 179 small business expensing, which allows small businesses to immediately expense up to $500,000 instead of depreciating them over time and there will be an additional 50 percent bonus depreciation for the purchase of new capital assets.
American Farm Bureau Federation President Bob Stallman praised Congress for passing the bill while noting that a long-term solution is needed.

"Thanks to tax provisions like Section 179 for small business expensing and bonus depreciation, hard-working Americans will be free to put their money directly back to work on their land and in their local communities," Stallman said. "

 
Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.